Mifepristone CAS: 84371-65-3
MF: C29H35NO2
MW: 429.59
A progesterone and glucocorticoid antagonist, suppresses VEGF production.

Mifepristone (CAS 84371-65-3)

Mifepristone | CAS 84371-65-3 is rated 5.0 out of 5 by 1.
  • y_2021, m_6, d_12, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.17
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203134, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 107ms
  • REVIEWS, PRODUCT
loading
5
1
4
0
3
0
2
0
1
0
Alternate Names: 11β-(4-Dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one; RU-486
Application: Mifepristone is a progesterone and glucocorticoid antagonist, suppresses VEGF production
CAS Number: 84371-65-3
Purity: ≥98%
Molecular Weight: 429.59
Molecular Formula: C29H35NO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).
loading

Mifepristone is a progesterone (PR) and glucocorticoid receptor (GR) antagonist which has demonstrated the ability to suppress activation of NFκB, a nuclear transcription factor that affects the expression of various adhesion molecules and several inflammatory genes. It is also an inhibitor of the progesterone receptor. Mifepristone has been found to decrease basal bcl-2 messenger RNA levels in CA1 neural regions and the dentate gyrus. Experiments have shown that mifepristone potentially exhibits an inhibitory effect on embryo implantation via regulation of FAS and FAS-L apoptosis gene expression. Additionally, mifepristone displays anti-angiogenic characteristics via suppression of vascular endothelial growth factor (VEGF) production. Mifepristone may also prevent intracellular peroxide accumulation and cell death induced by hydrogen peroxide, glutamate, β-amyloid protein, or neurotoxins that have been associated with certain neurodegenerative disorders.


References

1. Behl, C., et al. 1997. Eur. J. Neurosci. 9: 912-920. PMID: 9182944
2. Greb, R.R., et al. 1997. Hum. Reprod. 12: 1280-1292. PMID: 9222018
3. Gao, F., et al. 2001. Acta Pharmacol. Sin. 22: 524-529. PMID: 11747759
4. Sridhar, S., et al. 2001. Cancer Res. 61: 7179-7183. PMID: 11585752
5. Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955: 159-199. PMID: 11949945
6. McCullers, D.L., et al. 2002. Neuroscience. 109: 219-230. PMID: 11801359

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in water (partly), DMF (~30 mg/ml), ethanol (50 mg/ml), methanol, and DMSO (86 mg/ml at 25° C).
Storage :
Store at 4° C
Melting Point :
192-196° C
Boiling Point :
628.61° C at 760 mmHg (Predicted)
Density :
1.19 g/cm3 (Predicted)
Refractive Index :
n20D 1.62 (Predicted)
Optical Activity :
α20/D +149°, c = 0.55 in chloroform
IC50 :
Progesterone receptor: IC50 = 0.2 nM; PR dimerization and activation: IC50 = 0.6 nM; Glucocorticoid receptor: IC50 = 2.6 nM; ovarian cancer cell growth of SK-OV-3: IC50 = 6.25 µM; ovarian cancer cell growth of OV2008: IC50 = 6.91 µM
Ki Data :
PR: Ki= ~1 nM; GR: Ki= ~1 nM
pK Values :
pKa: 12.94 (Predicted), pKb: 5.49 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
KG2955000
PubChem CID :
Merck Index :
14: 6186
MDL Number :
MFCD00867226
Beilstein Registry :
5779404
SMILES :
CC#C[[email protected]@]1(CC[[email protected]@H]2[[email protected]@]1(C[[email protected]@H](C3=C4CCC(=O)C=C4CC[[email protected]@H]23)C5=CC=C(C=C5)N(C)C)C)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Mifepristone (CAS 84371-65-3)  Product Citations

See how others have used Mifepristone (CAS 84371-65-3). Click on the entry to view the PubMed entry .

Citations 1 to 10 of 13 total

PMID: # 31442299  2019. J. Neurochem.

PMID: # 29684377  Tocchetti, GN. et al. 2018. Biochem. Pharmacol. 154: 118-126.

PMID: # 29088702  Hangauer, MJ. et al. 2017. Nature. 551: 247-250.

PMID: # 28522271  Tsai, YC.|Tseng, JT.|Wang, CY.|Su, MT.|Huang, JY.|Kuo, PL.| et al. 2017. Mol Cell Endocrinol. 452: 74-83.

PMID: # 25817199  Wang, Y. et al. 2015. Acta Histochem. 117: 297-304.

PMID: # 25811655  2015. PLoS ONE. 10: e0121316.

PMID: # 23089292  2012. Eur J Pharm Sci. 47: 842-7.

PMID: # 17325386  Wang, Y. et al. 2007. J. Lipid Res. 48: 1062-1068.

PMID: # 17322380  Babbin, BA. et al. 2007. Am. J. Pathol. 170: 951-966.

PMID: # 17923680  Dirlam, A. et al. 2007. Mol. Cell. Biol. 27: 8713-8728.

Citations 1 to 10 of 13 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 126ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Babbin Babbin, BA. et al. (PubMed 17322380) used Mifepristone, a progesterone and glucocorticoid antagonist, to control RhoAV14-EGFP expression, in a mifepristone-inducible Caco-2 cell line expressing EGFP-tagged RhoAV14. -SCBT Publication Review
Date published: 2015-04-16
  • y_2021, m_6, d_12, h_18
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.17
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_203134, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 15ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.